Breaking News Headlines Today | Ground News

See every side of every news story

neurologylive.com image

News from neurologylive.com

Top neurologylive.com News

Cognitive Scores Improve With Lifestyle Changes, Trial Shows

Mindfulness · United States

Cognitive Scores Improve With Lifestyle Changes, Trial Shows

Coverage: 6 sources

(MedPage Today) -- TORONTO -- Two lifestyle interventions -- one structured, the other self-guided -- improved cognition in older adults at risk of cognitive decline, the 2-year U.S. POINTER trial showed. Global cognitive scores increased...See the Story

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

Alzheimer's Disease

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

100% Center coverage: 1 sources

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 28, 2025-See the Story

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

Alzheimer's Disease · Toronto

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

100% Center coverage: 1 sources

(MedPage Today) -- TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, researchers said here. Continued...See the Story

Breaking News Topics Related to neurologylive.com

B Cells as a Treatment Target in Myasthenia Gravis

Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.Maryland · Maryland Read Article

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.Alzheimer's Disease Read Article

Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.Read Article

Discussing Dyskinesia Treatment Options With Patients With Parkinson Disease

Panelists discuss how treatment decisions for complex cases like the 66-year-old man with severe dyskinesia and 4 hours of daily “off” time require individualized approaches based on patient tolerance, with options including delayed-release/extended-release amantadine (starting at lower doses in older patients due to hallucination risk), extended-release carbidopa-levodopa formulations, infusion pumps for potential deep priming effects, or deep …Read Article

Underdiagnosis and Differential Diagnosis of EDS in Patients With OSA

Panelists discuss how to differentiate true excessive daytime sleepiness from general fatigue or tiredness, emphasizing the importance of collaborative care with other specialists to address underlying mood disorders and comorbid conditions that may complicate diagnosis.Read Article

A Case of a 66-Year-Old Man With Parkinson Disease and Dyskinesia

Panelists discuss how a 66-year-old man with 8 years of Parkinson disease presenting with severe peak-dose dyskinesia affecting basic functions like eating and speaking, plus 4 hours of daily “off” time despite frequent dosing, represents a patient who should not have been allowed to progress to such advanced motor complications, emphasizing that the preferred approach is early intervention to treat motor fluctuations and dyskinesia as they deve…Parkinson's Disease Read Article

Phase 2 PRIMUS-AD Trial to Test Anti-Amyloid Oligomer PRI-002 in Alzheimer Disease

A groundbreaking phase 2 study evaluates PRI-002's potential to treat mild Alzheimer's symptoms, aiming for significant safety and efficacy insights by 2026.Alzheimer's Disease Read Article

Phase 3 Study Results of Obicetrapib on Alzheimer Disease Biomarker Progression: Philip Scheltens, MD, PhD

The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]Maryland · Maryland Read Article